Incorporation of immunotherapy into the treatment of metastatic neuroendocrine carcinoma of the cervix: A case report

• Ideal treatment for advanced neuroendocrine carcinoma of the cervix (NECC) remains unclear. • A patient with metastatic NECC experienced a durable complete response to multi-modal therapy that included atezolizumab. • Atezolizumab may improve response rates and overall survival when incorporated i...

Descripción completa

Detalles Bibliográficos
Autores principales: Suresh, Akanksha, Ferriss, James Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474144/
https://www.ncbi.nlm.nih.gov/pubmed/37663173
http://dx.doi.org/10.1016/j.gore.2023.101263
_version_ 1785100427393499136
author Suresh, Akanksha
Ferriss, James Stuart
author_facet Suresh, Akanksha
Ferriss, James Stuart
author_sort Suresh, Akanksha
collection PubMed
description • Ideal treatment for advanced neuroendocrine carcinoma of the cervix (NECC) remains unclear. • A patient with metastatic NECC experienced a durable complete response to multi-modal therapy that included atezolizumab. • Atezolizumab may improve response rates and overall survival when incorporated into therapy for NECC.
format Online
Article
Text
id pubmed-10474144
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104741442023-09-03 Incorporation of immunotherapy into the treatment of metastatic neuroendocrine carcinoma of the cervix: A case report Suresh, Akanksha Ferriss, James Stuart Gynecol Oncol Rep Case Report • Ideal treatment for advanced neuroendocrine carcinoma of the cervix (NECC) remains unclear. • A patient with metastatic NECC experienced a durable complete response to multi-modal therapy that included atezolizumab. • Atezolizumab may improve response rates and overall survival when incorporated into therapy for NECC. Elsevier 2023-08-22 /pmc/articles/PMC10474144/ /pubmed/37663173 http://dx.doi.org/10.1016/j.gore.2023.101263 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Suresh, Akanksha
Ferriss, James Stuart
Incorporation of immunotherapy into the treatment of metastatic neuroendocrine carcinoma of the cervix: A case report
title Incorporation of immunotherapy into the treatment of metastatic neuroendocrine carcinoma of the cervix: A case report
title_full Incorporation of immunotherapy into the treatment of metastatic neuroendocrine carcinoma of the cervix: A case report
title_fullStr Incorporation of immunotherapy into the treatment of metastatic neuroendocrine carcinoma of the cervix: A case report
title_full_unstemmed Incorporation of immunotherapy into the treatment of metastatic neuroendocrine carcinoma of the cervix: A case report
title_short Incorporation of immunotherapy into the treatment of metastatic neuroendocrine carcinoma of the cervix: A case report
title_sort incorporation of immunotherapy into the treatment of metastatic neuroendocrine carcinoma of the cervix: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474144/
https://www.ncbi.nlm.nih.gov/pubmed/37663173
http://dx.doi.org/10.1016/j.gore.2023.101263
work_keys_str_mv AT sureshakanksha incorporationofimmunotherapyintothetreatmentofmetastaticneuroendocrinecarcinomaofthecervixacasereport
AT ferrissjamesstuart incorporationofimmunotherapyintothetreatmentofmetastaticneuroendocrinecarcinomaofthecervixacasereport

Ejemplares similares